| Osmotic drug delivery system |
2022-11-21 |
2023-8-17 |
|
| Modified release preparations containing oxcarbazepine and derivatives thereof |
2022-11-15 |
2023-3-16 |
|
| Method of treatment of attention deficit/hyperactivity disorder (adhd) |
2022-8-26 |
2023-3-30 |
|
| Formulations of mazindol |
2022-8-09 |
2023-7-06 |
|
| Use of higher doses of modified release huperzine formulations |
2022-6-03 |
2023-3-23 |
|
| Derivatives of substituted morpholines and uses thereof |
2022-5-25 |
2022-9-22 |
|
| Methods, system, and kit for monitoring, diagnosing, and treating impulsive … |
2022-3-03 |
2022-3-24 |
|
| Methods for producing viloxazine salts and novel polymorphs thereof |
2021-8-04 |
2022-1-27 |
|
| Stabilized formulations of cns compounds |
2021-6-25 |
2021-10-21 |
|
| Once Daily Formulations Of Tetracyclines |
2021-2-25 |
2022-1-20 |
|
| Modified release formulations of viloxazine |
2020-9-18 |
2020-10-08 |
|
| Methods of producing molindone and its salts |
2020-4-30 |
2020-8-20 |
|
| Method of treatment of cns disorders |
2019-11-08 |
2020-3-05 |
|
| Method of treatment of aggression |
2019-1-04 |
2023-5-02 |
2023-5-02 |
| Method of treatment of aggression |
2018-4-16 |
2018-5-10 |
|
| Sustained-release formulations of topiramate |
2017-3-30 |
2017-9-21 |
|
| Enhanced immediate release formulations of topiramate |
2015-1-20 |
2015-7-02 |
|
| FORMS OF PHARMACEUTICAL DOSAGE CONTROLLED DETERMINATION WITH PHARMACEUTICAL … |
2014-12-29 |
2017-1-25 |
|
| Drug formulations having reduced abuse potential |
2014-12-08 |
2015-6-04 |
|
| Method of treatment of depression |
2014-8-25 |
2014-12-25 |
|
| Enhanced formulations of lamotrigine |
2013-11-05 |
2014-3-20 |
|
| Controlled release compositions of gamma-hydroxybutyrate |
2013-9-24 |
2014-2-06 |
|
| Controlled released preparations of oxcarbazepine having sigmoidal release … |
2013-1-17 |
2015-7-16 |
2015-7-16 |
| Once daily trospium chloride treatment method |
2012-9-19 |
2013-4-11 |
|
| A TREATMENT METHOD OF A NEUROLOGICAL DISORDER |
2012-2-02 |
2012-4-16 |
|
| Use of a mixture of two or more enteric materials to regulate drug release via … |
2011-1-10 |
2014-8-19 |
2014-8-19 |
| Formulations of desvenlafaxine |
2010-2-02 |
2010-8-12 |
|
| Controlled release formulations of pramipexole |
2009-6-05 |
2009-12-10 |
|
| Use of isoindoles for the treatment of neurobehavioral disorders |
2009-6-03 |
2009-12-24 |
|
| Controlled release formulations of alprazolam |
2009-5-07 |
2011-2-23 |
|
| Topiramate compositions and methods of enhancing its bioavailability |
2007-8-31 |
2008-4-10 |
|
| Absorption enhancing agents |
2007-4-27 |
2007-10-25 |
|
| Modified release tablet formulations with enhanced mechanical properties |
2006-7-28 |
2008-4-16 |
|
| Modified release tablet formulations with enhanced mechanical properties |
2006-7-28 |
2007-5-10 |
|
| Orally administrable extended release pellet and tablet formulations of a … |
2005-12-09 |
2007-6-14 |
|
| Less abusable pharmaceutical preparations |
2005-10-14 |
2014-12-03 |
2014-12-03 |
| Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
2004-11-24 |
2012-8-15 |
|
| Compositions of quaternary ammonium compounds containing bioavailability … |
2004-11-04 |
2005-6-09 |
|
| Sustained release of positively charged pharmacologically active molecules from … |
2004-11-04 |
2012-6-13 |
|
| Osmotic delivery of therapeutic compounds by solubility enhancement |
2004-9-07 |
2013-11-05 |
2013-11-05 |
| Fluidization of particles for encapsulation in oral dosage pharmaceutical … |
2004-5-12 |
2010-10-12 |
2010-10-12 |
| Pharmaceutical compositions releasing their active agents from a buccal or … |
2004-4-13 |
2006-1-25 |
|
| Accelerated culture system for intestinal epithelial cell monolayers |
2004-3-11 |
2005-12-21 |
|
| Drug formulation and delivery using crystalline methylated cyclodextrins |
2004-2-02 |
2004-8-19 |
|
| Drug formulation and delivery using crystalline methylated cyclodextrins |
2004-2-02 |
2004-8-12 |
|
| Absorption enhancing agents |
2004-1-22 |
2005-11-23 |
|
| Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives … |
2003-6-27 |
2004-6-10 |
|
| Treatment of oppositional defiant disorder and conduct disorder with 5- … |
2003-5-07 |
2004-6-17 |
|
| Pharmaceutical formulations with improved bioavailability |
2003-4-29 |
2009-3-18 |
2009-3-18 |